CA
PVLA

Cetera Advisors’s Palvella Therapeutics PVLA Stock Holding History

Cetera Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-141
Closed -$43K – 1544
2021
Q4 		$43K Buy
141
+15
+12% +$4.8K ﹤0.01% 1403
2021
Q3 		$52K Buy
+126
New +$43.9K ﹤0.01% 1373

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cetera Advisors's PVLA Position: Q1 2022 in Review

Cetera Advisors sold out of Palvella Therapeutics (PVLA) in Q1 2022, closing a stake of 141 shares — an estimated $43K sold.

Cetera Advisors first reported a position in PVLA in Q3 2021 and held it in 2 quarters. The position peaked at $52K in Q3 2021. 71 funds tracked by Wall St. Rank hold PVLA as of Q1 2022.

  • Cetera Advisors reported no remaining Palvella Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Cetera Advisors sold 141 Palvella Therapeutics shares in Q1 2022, an estimated $43K.
  • Cetera Advisors first reported a position in Palvella Therapeutics in Q3 2021 and held it in 2 quarters.
  • Cetera Advisors's Palvella Therapeutics position peaked at $52K in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2022.

Based on Cetera Advisors's 13F filing for Q1 2022, filed 12 May 2022.